Compare Amgen, Inc. (AMGN) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vale SA — how do they compare? Amgen, Inc. trades at $362.02 (market cap $196.12B), while Vale SA trades at $14.39 (market cap $60.94B). The key difference: Amgen, Inc. is far larger — about 3.2× Vale SA's market cap, and Vale SA pays the higher dividend (8.7%). Which is the better fit depends on your goals.
| AMGN | VALE | |
|---|---|---|
Market Cap | $196.12B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $17.82 |
52-Week Low | $271.18 | $9.53 |
Enterprise Value | $241.41B | $77.86B |
Dividend Yield | 2.77% | 8.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VALE trades at $14.46, up 1.69% with mixed earnings performance including a Q3 2025 beat but recent misses. Technical indicators show bearish momentum with oversold RSI signals. The company maintains solid cash flow generation ($2.42B net in 2025) despite declining profit margins from 42.85% in 2022 to 6.12% in 2025. Recent news highlights $2.56B decarbonization investments and governance developments.
VALE presents a cautious opportunity with analyst consensus at $17.50 (21% upside) but faces margin compression and debt increases. The stock's value proposition hinges on commodity price recovery and successful execution of efficiency initiatives amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
